Takeda Is Focused on Innovation Through R&D, CEO Says

The CEO of Takeda Pharmaceutical discusses the integration with Shire, highlighting the progress made in leadership and strategy. He addresses the company's debt management strategy, aiming to maintain an investment-grade rating through cash flow and asset disposals. The focus is on divesting non-core assets to streamline operations. The CEO also emphasizes the importance of innovation and strategic focus in selected therapy areas to stay competitive in the pharmaceutical industry.

What percentage of Takeda's business is considered core assets, and what is the plan for the non-core assets?

What are the four therapy areas that Takeda has selected to concentrate on, according to the CEO?